Compare · AZN vs COGT
AZN vs COGT
Side-by-side comparison of AstraZeneca PLC (AZN) and Cogent Biosciences Inc. (COGT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and COGT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $277.21B, about 57.3x COGT ($4.84B).
- AZN has been more active in the news (22 items in the past 4 weeks vs 4 for COGT).
- AZN has more recent analyst coverage (25 ratings vs 17 for COGT).
- Company
- AstraZeneca PLC
- Cogent Biosciences Inc.
- Price
- -
- -
- Market cap
- $277.21B
- $4.84B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2018
- News (4w)
- 22
- 4
- Recent ratings
- 25
- 17
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Cogent Biosciences Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- SEC Form 6-K filed by AstraZeneca PLC
Latest COGT
- SEC Form 10-Q filed by Cogent Biosciences Inc.
- Cogent Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
- Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
- SEC Form 4 filed by Cogent Biosciences Inc.
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
- SEC Form 8-K filed by Cogent Biosciences Inc.
- Director Morris Arlene exercised 45,510 shares at a strike of $5.39 and sold $1,689,493 worth of shares (45,510 units at $37.12) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Cogent Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.